World of DTC Marketing
JUNE 22, 2022
PBMs, insurers, pharma companies, and hospitals don’t want to give up their profits even if it’s better for the general population. Then there is the cost of generic drugs. billion in 2020 if it had purchased 77 of 89 drugs from Cuban’s firm.
World of DTC Marketing
JULY 27, 2022
Pharma companies have very little control over patients’ prices for their Rxs. A drug’s out-of-pocket cost is primarily the result of decisions made by insurance companies and pharmacy benefit managers (PBMs). Insurers and PBMs have even devised schemes to overcharge patients for generic drugs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JUNE 5, 2023
Earlier this year, Sun Pharmaceutical Industries , one of India’s largest generic drug producers, reported a major cybersecurity breach , impacting its business operations. Pharma companies around the world have also faced similar threats , some of which have impacted national security and public health.
Pharmaceutical Technology
JULY 15, 2022
CivicaRx is a non-profit generic drug company producing affordable insulin biosimilars in collaboration with the Juvenile Diabetes Research Foundation (JDRF). Most of the US insulin market is controlled by three pharma companies: Sanofi, Eli Lilly, and Novo Nordisk. In-house manufacturing the norm.
pharmaphorum
SEPTEMBER 9, 2022
Pharma companies are “highly vulnerable” to the effects of climate change, due to their reliance on global networks. To meet the growing demand and market opportunity, a pharma company must ensure it has the resources, capacity, and supply chain to grow.”. Vulnerability . Making plans is not enough.
Drug Discovery World
MARCH 29, 2023
Regulatory data protection (RDP) period RDP refers to the time when generic drug makers cannot refer to an innovator drug’s data to obtain a marketing authorisation 2. This looks like it may change shape in the future for the region, if the proposal put forward by the commission is adopted.
pharmaphorum
AUGUST 20, 2020
Teva mainly administered the scheme through its specialty pharmacy, Advanced Care Scripts (ACS) with payments amounting to around $300 million during the period, according to the complaint. During that period Teva raised the price from around $17,000 per year to over $73,000 per year, the DoJ alleges.
Expert insights. Personalized for you.
227 
Let's personalize your content